 |
|
|
|
|
|
 Title: |
US6231852:
Method for reducing BCL-2 expressing cells resistance to death
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Bredesen, Dale E.; Rancho Santa Fe, CA
|
| Assignee: |
The Regents of the University of California, Oakland, CA
other patents from UNIVERSITY OF CALIFORNIA, THE REGENTS OF (599425) (approx. 4,840)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
2001-05-15
/ 1996-09-03
|
| Application Number: |
US1996000707055
|
| IPC Code: |
Advanced:
A61K 31/05;
A61K 31/06;
A61K 31/085;
A61K 31/16;
A61K 31/444;
C12N 5/00;
Core:
A61K 31/045;
A61K 31/075;
A61K 31/4427;
more...
IPC-7:
A01N 37/18;
A61K 38/44;
A61K 39/385;
A61K 39/395;
|
| ECLA Code: |
A61K31/05; A61K31/06; A61K31/085; A61K31/16; A61K31/444; C12N5/00;
|
| U.S. Class: |
Current:
424/094.4;
424/138.1;
424/174.1;
424/175.1;
424/195.11;
424/613;
424/616;
424/617;
435/375;
514/002;
514/885;
Original:
424/094.4;
424/613;
424/617;
424/616;
424/175.1;
424/138.1;
424/174.1;
424/195.11;
514/002;
514/885;
435/240.2;
|
| Field of Search: |
435/240.2
424/94.4,613,617,616
514/002,885
|
| Government Interest: |
This invention was made with support under Grant No. NS27812 from the National Institutes of Health. Accordingly, the United States Government has certain rights in this invention.
|
| Priority Number: |
| 1996-09-03 |
US1996000707055 |
| 1996-03-15 |
US1996000616604 |
| 1993-11-18 |
US1993000154281 |
|
| Abstract: |
Methods for controlling cell death when the cell is exposed to one or more potentially lethal cellular insults. In one method, cell death is inhibited by introducing a reactive oxygen species limiter into the cell which prevents the build up of lethal levels of reactive oxygen species when the cell is exposed to a cellular insult. In another method, cell death is promoted in cancer cells or other proliferating cells which are naturally resistant to lethal cellular insults. The method involves neutralizing reactive oxygen species limiters, such as bcl-2, which occur naturally in cancer cells and which prevent the build up of reactive oxygen species within the cancer cells when they are exposed to lethal cellular insult. Neutralizing the reactive oxygen species limiter leaves the cancer cell unable to protect itself when cellular insult causes increases in the level of reactive oxygen species. The result is an increase in cell death.
|
| Attorney, Agent or Firm: |
Gray Cary Ware & Freidenrich LLP ;
Haile, Lisa A. ;
|
| Primary / Asst. Examiners: |
Minnifield, Mita;
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
|
|
|
|
|
|
| Related Applications: |
| Application Number |
Filed |
Patent |
Pub. Date |
Title |
|---|
| US1996000616604 | 1996-03-15 |
|
|
|
| US1993000154281 | 1993-11-18 |
|
|
|
|
|
|
|
|
|
|
| Parent Case: |
This application is Continuation-in-Part Application of U.S. application Ser. No. 08/616,604, filed Mar. 15, 1996, now abandoned, which is a continuation of U.S. application Ser. No. 08/154,281, filed Nov. 18, 1993, now abandoned.
|
| Designated Country: |
AL AM AP AT AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE EP ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU
|
| Family: |
Show 4 known family members
|
First Claim:
Show all 18 claims |
What is claimed is:
1. A method for inhibiting proliferation of cells that endogenously produce bcl-2 protein, said method comprising:
- administering to the cells an amount of one or more agents effective to impair the reactive oxygen species limiting-activity of bcl-2 in the cells, and
- subjecting the cells to a cellular insult that triggers spontaneous production of lethal levels of intracellular reactive oxygen species in the cells, wherein the agent and the cellular insult are different treatments,
- whereby proliferation of the cells so treated is inhibited as compared to that of untreated cells exposed to the cellular insult.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 2 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
|
| Other Abstract Info: |
CHEMABS 127(17)229654E
CHEMABS 134(24)336240H
CHEMABS 134(24)336240H
DERABS C1997-470565
|
| Other References: |
Hockenbery et al., "Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death," Nov. 22, 1990, Nature, vol. 348, pp. 334-336.
Zhong et al., "BCL-2 Inhibits Apoptosis in Multiple Neural Cell Types," Abst. 25.11, Society for Neuroscience Abstracts, vol. 18, 1992.
Nunez et al., "Deregulated Bcl-2 Gene Expression Selectively Prolongs Survival of Growth Factor-Deprived Hemopoietic Cell Lines," May 1, 1990, Journal of Immunology, vol. 144, No. 9 pp. 3602-3610.
Zhong et al., "bcl-2 inhibits death of central neural cells induced by multiple agents," May 1993, Proc. Natl. Acad. Sci., vol. 90, pp. 4533-4537.
Mah et al. "The Protooncogene bcl-2 Inhibits Apoptosis in PC12 Cells," 1993, J. Neurochem, vol. 60, No. 3, pp. 1183-1185.
Garcia et al., "Prevention of Programmed Cell Death of Sympathetic Neurons by the bcl-2 Proto-Oncogene," Oct. 9, 1992, Science, vol. 258, pp. 302-304.
Martinou et al., "The bcl-2 Proto-Oncogene Protects Neurons From Naturally Occurring Cell Death In Vivo," Abst. 279.16, Society for Neuroscience Abstracts, vol. 19, 1993.
Merry et al., "bcl-2 protein expression is widespread in the developing nervous system and retained in the adult PNS," Development 120, 301-311 (1994).
Allsopp et al., "The Proto-Oncogene bcl-2 Can Selectively Rescue Neurotrophic Factor-Dependent Neurons From Apoptosis," Cell, vol. 73, 295-307, 1993.
Kane et al., "Bcl-2 Inhibits Neural Cell Death by Decreasing the Production of Reactive Oxygen Species," Abst. 279.17, Society for Neuroscience Abstracts, vol. 19, 1993.
Zhong et al., "Bcl-2 blocks glutamate toxicity in neural cell lines," Molecular Brain Research, 19 (1993) 353-355.
Wood et al, Biochemistry: A Problems Approach (1980) pp 232-233.*
DeVita et al, Cancer: Principles and Practice of Oncology, J.B. Lippincott Co., Philadelphia (1993) p 282.*
Dornand et al, Immunology: 68(3) pp 384-391 (1989).*
Hockenberry et al PNAS: 88 pp 6961-6965 (1991).*
Clark et al, Infection and Immunity, (1983) 39(1) Abstract.
|
|
 Nominate this for the Gallery...
|
|
